Journal of Clinical Oncology
Articles in this Issue
Comparative outcomes of HBV-related vs. HCV-related hepatocellular carcinoma under targeted therapy: A retrospective study.
e16319 Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide, with hepatitis B virus (HBV) and hepatitis C vir...
Famitinib for familial adenomatous polyposis-associated aggressive desmoid tumors: 32-month follow-up from a single-center exploratory study.
10611 Background: Desmoid tumors (DTs) associated with familial adenomatous polyposis (FAP) are rare, locally aggressive soft-tissue tumors with high recu...
Omission of concurrent chemotherapy in and out of a phase III randomized controlled trial for stage II nasopharyngeal carcinoma.
6085 Background: In the era of intensity-modulated radiotherapy (IMRT), the precision of radiotherapy has been greatly enhanced, allowing for more precise...
METscreen: Decision-support tool for metastatic colorectal cancer patients based on organoid drug screening in a clinical research feasibility study.
e15582 Background: Cancer patients’ survival is directly related to timely identification of effective systemic oncological treatment capable of avoiding...
Representation and outcomes for older patients in phase 3 clinical trials for metastatic and unresectable head and neck squamous cell carcinoma (HNSCC): A systematic review.
e18021 Background: Despite older adults (age 65+) constituting the majority (~ 70%) of all patients with head and neck squamous cell carcinoma (HNSCC), a...
Optimizing clinically actionable biomarker detection in advanced cancers by next generation sequencing (NGS) panel and specimen type.
e15042 Background: There are many factors to consider when choosing the optimal NGS approach for successful biomarker testing. We present NGS data from 82...
Leveraging EHRs and a phenome-wide association study to identify pre-diagnostic clinical markers in early-onset colorectal cancer.
3622 Background: The incidence of colorectal cancer (CRC) has undergone a significant demographic shift, with diagnosis in individuals under 55 years esca...
The association of cancer history with markers of cognitive decline in a large US national survey registry.
11136 Background: Cancer is known to cause health complications, including heart and kidney disease, but its long-term impact on cognition is less underst...
VERSATILE-003: A phase 3, randomized, open-label trial of PDS0101 and pembrolizumab compared with pembrolizumab for first-line treatment of patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.
TPS6111 Background: Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) has surpassed cervical cancer as the most common HPV-...
Phase II clinical trial of S-1 and paclitaxel in combination followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as neoadjuvant treatment for HER2-negative, stage II/III breast cancer: 10-year follow-up results.
e12605 Background: The sequential combination of anthracyclines and taxanes is a standard in the neoadjuvant and adjuvant settings for breast cancer. Prec...
Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with fluorouracil, leucovorin, and budigalimab in locally advanced/metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (a/m GEA).
TPS4202 Background: The MET proto-oncogene and its receptor tyrosine kinase gene product (c-Met protein) are involved in normal ce...
Use of 177Lut-PSMA in metastatic castrate-resistant prostate cancer in the post-chemotherapy setting: Early vs late treatment.
e17168 Background: Prostate cancer is the most prevalent cancer and the second leading cancer related death in men in the USA. Radical prostatectomy repre...
Venous thrombosis prophylaxis in oncology: Knowledge, practice, and attitude study among oncologists in Armenia.
e21027 Background: Increased risk of venous thromboembolism (VTE) is observed among patients with malignancies, characterized by an incidence of 5.8 per 1...
The efficacy and safety of donafenib as postoperative adjuvant therapy in patients at high risk of recurrence following radical resection of hepatocellular carcinoma (HCC): A multicenter retrospective study.
4134 Background: Hepatectomy is a crucial treatment for long-term survival in patients with HCC; however, the high recurrence rate significantly impacts p...
Prognostic value of circulating tumor DNA (ctDNA) detection by PhasED-Seq after axicabtagene ciloleucel (axi-cel) therapy in relapsed/refractory large B-cell lymphoma (LBCL).
e15043 Background: In ZUMA-7, a phase 3 randomized trial to evaluate axi-cel treatment in LBCL (NCT03391466), most patients responded well to axi-cel, but...
Phase I study of Ori-C101, an armored GPC3-directed CAR-T, in patients with advanced hepatocellular carcinoma (HCC).
4084 Background: Previously, we reported the results of Ori-C101 from investigator initiated trial in China (ChiCTR1900028121). The data demonstrated that...
ASCOmind: Is instant ASCO abstract analysis possible with AI agents?
7557 Background: The ASCO Annual Meeting receives thousands of abstracts annually on ongoing therapies. Extracting actionable insights from this large vol...
BASECAMP-1: An approach to improve patient screening efficiency and to provide large datasets for precision medicine clinical trials.
e23020 Background: Precision medicine studies must overcome the challenges of identifying patients with uncommon molecular targets and small cohort sizes...
First-in-class TMBIM6 therapeutics: Overcoming limitations in current oncology therapies through ERAD-II induced paraptosis.
e15120 Background: Despite advances in cancer treatment, significant challenges remain, such as immune evasion, chemoresistance, and reliance on apoptotic...
Factors influencing completion of cancer therapy in heart transplant recipients with de novo malignancies.
e23058 Background: Among recipients of solid organ transplants, heart transplant recipients are at highest risk of developing malignancies due to high lev...
Molecular characteristics of non-small cell lung cancer in Venezuela: A multicenter study.
e20546 Background: In 2022, an estimate of 236,740 new cases of lung cancer were recorded in the United States, with 130,180 estimated deaths, being the l...
Lymph node excision (LNEx) for patients with stage III melanoma with one clinically positive node: Excision of Lymph Node trial (EXCILYNT).
TPS9608 Background: When melanoma metastases are detected clinically in regional lymph nodes (cLNs) without distant metastasis, standard surgical manageme...
Race/ethnicity, socioeconomic status, and health system factors related to stage of presentation for newly diagnosed cancers in and insured population in southern California, 2015–2020.
e13810 Background: Stage of cancer at presentation may influence overall survival. Factors contributing to stage at presentation include access to care, p...
Unresectable advanced cutaneous squamous cell carcinoma: Patient characteristics and outcomes following anti PD-1 treatment from a single institution.
e21545 Background: Patients (pts) with unresectable advanced cutaneous squamous cell carcinoma (UACSCC) have favorable outcomes following FDA approved ant...
Unveiling the role of sodium glucose cotransporter-2 inhibitors in hepatocellular carcinoma patients with cirrhosis: A comparative global cohort study.
4138 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, and is often associated with chronic liver disea...